目前可用的静脉用免疫球蛋白含有针对严重急性呼吸综合征冠状病毒 2 抗原的抗体。
Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens.
机构信息
Research & Development - Bioscience Industrial Group, Grifols, Barcelona, Spain.
出版信息
Immunotherapy. 2020 Jun;12(8):571-576. doi: 10.2217/imt-2020-0095. Epub 2020 May 12.
Abstract
There is a critical need for effective therapies that are immediately available to control the spread of COVID-19 disease. Gamunex-C and Flebogamma DIF (Grifols) intravenous immunoglobulin (IVIG) products were tested using ELISA techniques for antibodies against several antigens of human common betacoronaviruses that may crossreact with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. Both IVIGs showed consistent reactivity to components of the tested viruses. Positive crossreactivity was seen in SARS-CoV, middle east respiratory syndrome-CoV and SARS-CoV-2. For SARS-CoV-2, positive reactivity was observed at IVIG concentrations ranging from 100 μg/ml with Gamunex-C to 1 mg/ml with Flebogamma 5% DIF. Gamunex-C and Flebogamma DIF contain antibodies reacting against SARS-CoV-2 antigens. Studies to confirm the utility of IVIG preparations for COVID-19 management may be warranted.
摘要
目前急需有效的治疗方法来控制 COVID-19 疾病的传播。Gamunex-C 和 Flebogamma DIF（基立福）静脉注射用免疫球蛋白（IVIG）产品已通过 ELISA 技术针对几种可能与严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）病毒发生交叉反应的人常见β冠状病毒的抗原进行了测试。两种 IVIG 均对测试病毒的成分表现出一致的反应性。在 SARS-CoV、中东呼吸综合征-CoV 和 SARS-CoV-2 中均观察到阳性交叉反应。对于 SARS-CoV-2，在 Gamunex-C 的 100μg/ml 至 Flebogamma 5% DIF 的 1mg/ml 的 IVIG 浓度范围内观察到阳性反应。Gamunex-C 和 Flebogamma DIF 含有针对 SARS-CoV-2 抗原的抗体。可能需要进行研究以确认 IVIG 制剂在 COVID-19 管理中的效用。
相似文献
1
Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens.目前可用的静脉用免疫球蛋白含有针对严重急性呼吸综合征冠状病毒 2 抗原的抗体。
Immunotherapy. 2020 Jun;12(8):571-576. doi: 10.2217/imt-2020-0095. Epub 2020 May 12.
2
Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins.目前的静脉注射免疫球蛋白对 SARS-CoV-2 具有交叉中和活性。
Immunotherapy. 2020 Dec;12(17):1247-1255. doi: 10.2217/imt-2020-0220. Epub 2020 Sep 8.
3
Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia.关于 SARS-CoV-2 感染潜在发病机制的假说——病毒性肺炎患者免疫变化的综述。
Emerg Microbes Infect. 2020 Dec;9(1):727-732. doi: 10.1080/22221751.2020.1746199.
4
Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections.新冠病毒和非典病毒感染之间的交叉反应性抗体反应。
Cell Rep. 2020 Jun 2;31(9):107725. doi: 10.1016/j.celrep.2020.107725. Epub 2020 May 18.
5
Anti-SARS-CoV-2 Antibodies Within IVIg Preparations: Cross-Reactivities With Seasonal Coronaviruses, Natural Autoimmunity, and Therapeutic Implications.静脉注射免疫球蛋白制剂中的抗 SARS-CoV-2 抗体：与季节性冠状病毒、天然自身免疫反应的交叉反应性及其治疗意义。
Front Immunol. 2021 Feb 17;12:627285. doi: 10.3389/fimmu.2021.627285. eCollection 2021.
6
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.人类单克隆 SARS-CoV 抗体对 SARS-CoV-2 的交叉中和作用。
Nature. 2020 Jul;583(7815):290-295. doi: 10.1038/s41586-020-2349-y. Epub 2020 May 18.
7
The possible of immunotherapy for COVID-19: A systematic review.免疫疗法治疗 COVID-19 的可能性：系统评价。
Int Immunopharmacol. 2020 Jun;83:106455. doi: 10.1016/j.intimp.2020.106455. Epub 2020 Apr 2.
8
Monoclonal antibodies for the S2 subunit of spike of SARS-CoV-1 cross-react with the newly-emerged SARS-CoV-2.针对 SARS-CoV-1 刺突蛋白 S2 亚基的单克隆抗体与新出现的 SARS-CoV-2 发生交叉反应。
Euro Surveill. 2020 Jul;25(28). doi: 10.2807/1560-7917.ES.2020.25.28.2000291.
9
Passive Immunity for Coronavirus Disease 2019: A Commentary on Therapeutic Aspects Including Convalescent Plasma.《关于 2019 年冠状病毒病的被动免疫：包括恢复期血浆在内的治疗方面的述评》
Semin Thromb Hemost. 2020 Oct;46(7):796-803. doi: 10.1055/s-0040-1712157. Epub 2020 Jun 11.
10
Serological differentiation between COVID-19 and SARS infections.新冠病毒与 SARS 感染的血清学鉴别。
Emerg Microbes Infect. 2020 Dec;9(1):1497-1505. doi: 10.1080/22221751.2020.1780951.
引用本文的文献
1
An Overview of the Strategies to Boost SARS-CoV-2-Specific Immunity in People with Inborn Errors of Immunity.提高免疫缺陷患者中针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）特异性免疫的策略概述
Vaccines (Basel). 2024 Jun 18;12(6):675. doi: 10.3390/vaccines12060675.
2
Evaluation of the Efficacy and Safety of Intravenous Immunoglobulin (IVIG) in Moderate-to-Severe Hospitalized COVID-19 Patients: A Randomized, Open-Label Parallel-Group Study.静脉注射免疫球蛋白（IVIG）治疗中重度住院COVID-19患者的疗效和安全性评估：一项随机、开放标签平行组研究。
Can J Infect Dis Med Microbiol. 2024 May 21;2024:7209380. doi: 10.1155/2024/7209380. eCollection 2024.
3
Efficacy of intravenous immunoglobulin (IVIg) on COVID-19-related neurological disorders over the last 2 years: an up-to-date narrative review.过去两年静脉注射免疫球蛋白（IVIg）对新型冠状病毒肺炎相关神经系统疾病的疗效：最新叙述性综述
Front Neurosci. 2023 Apr 25;17:1159929. doi: 10.3389/fnins.2023.1159929. eCollection 2023.
4
Convalescent plasma for people with COVID-19: a living systematic review.COVID-19 患者恢复期血浆治疗：一项实时系统评价。
Cochrane Database Syst Rev. 2023 May 10;5(5):CD013600. doi: 10.1002/14651858.CD013600.pub6.
5
Convalescent plasma for people with COVID-19: a living systematic review.COVID-19 患者恢复期血浆治疗：一项实时系统评价。
Cochrane Database Syst Rev. 2023 Feb 1;2(2):CD013600. doi: 10.1002/14651858.CD013600.pub5.
6
IgG response to spike protein of SARS-CoV-2 in healthy individuals and potential of intravenous IgG as treatment for COVID-19.健康个体对 SARS-CoV-2 刺突蛋白的 IgG 反应和静脉注射 IgG 作为 COVID-19 治疗的潜力。
Virol J. 2022 Nov 13;19(1):186. doi: 10.1186/s12985-022-01921-z.
7
Humoral cross-coronavirus responses against the S2 region in children with Kawasaki disease.川崎病患儿针对 S2 区的体液交叉冠状病毒反应。
Virology. 2022 Oct;575:83-90. doi: 10.1016/j.virol.2022.08.010. Epub 2022 Sep 2.
8
Recent advances in passive immunotherapies for COVID-19: The Evidence-Based approaches and clinical trials.新型冠状病毒肺炎被动免疫治疗的最新进展：基于证据的方法和临床试验。
Int Immunopharmacol. 2022 Aug;109:108786. doi: 10.1016/j.intimp.2022.108786. Epub 2022 Apr 21.
9
Impact of Hypogammaglobulinemia on the Course of COVID-19 in a Non-Intensive Care Setting: A Single-Center Retrospective Cohort Study.非重症监护环境中低丙种球蛋白血症对 COVID-19 病程的影响：一项单中心回顾性队列研究。
Front Immunol. 2022 Mar 10;13:842643. doi: 10.3389/fimmu.2022.842643. eCollection 2022.
10
Therapeutic Strategies for COVID-19 Lung Disease in Children.儿童新冠病毒肺炎的治疗策略
Front Pediatr. 2022 Mar 7;10:829521. doi: 10.3389/fped.2022.829521. eCollection 2022.
本文引用的文献
1
Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover.两名 X 连锁无丙种球蛋白血症患者因 COVID-19 出现肺炎表现，但已康复。
Pediatr Allergy Immunol. 2020 Jul;31(5):565-569. doi: 10.1111/pai.13263. Epub 2020 May 19.
2
Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19.常规静脉注射免疫球蛋白治疗对新型冠状病毒肺炎（COVID-19）重症肺炎患者预后的影响。
J Infect. 2020 Aug;81(2):318-356. doi: 10.1016/j.jinf.2020.03.044. Epub 2020 Apr 10.
3
High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019.大剂量静脉注射免疫球蛋白作为新型冠状病毒肺炎病情恶化患者的一种治疗选择
Open Forum Infect Dis. 2020 Mar 21;7(3):ofaa102. doi: 10.1093/ofid/ofaa102. eCollection 2020 Mar.
4
Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV.SARS-CoV-2 刺突糖蛋白的特征及其对病毒进入的影响，以及与 SARS-CoV 的免疫交叉反应性。
Nat Commun. 2020 Mar 27;11(1):1620. doi: 10.1038/s41467-020-15562-9.
5
Strategies for the prevention and management of coronavirus disease 2019.新型冠状病毒肺炎的预防和管理策略。
Eur Respir J. 2020 Apr 16;55(4). doi: 10.1183/13993003.00597-2020. Print 2020 Apr.
6
Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19).分析早期体液免疫反应以诊断新型冠状病毒病（COVID-19）。
Clin Infect Dis. 2020 Jul 28;71(15):778-785. doi: 10.1093/cid/ciaa310.
7
COVID-19: consider cytokine storm syndromes and immunosuppression.2019冠状病毒病：考虑细胞因子风暴综合征和免疫抑制。
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
8
Is COVID-19 receiving ADE from other coronaviruses?新冠病毒是否会从其他冠状病毒中获得增强效应？
Microbes Infect. 2020 Mar;22(2):72-73. doi: 10.1016/j.micinf.2020.02.006. Epub 2020 Feb 22.
9
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
10
Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry.抗体依赖增强作用促进冠状病毒进入的分子机制。
J Virol. 2020 Feb 14;94(5). doi: 10.1128/JVI.02015-19.
Zotero 插件